WP 1303

Drug Profile

WP 1303

Alternative Names: H-1129; WP-1303

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer D. Western Therapeutics Institute; Wakamoto
  • Class Antiglaucomas; Small molecules
  • Mechanism of Action HSP90 heat-shock protein modulators; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma; Ocular hypertension

Most Recent Events

  • 31 Dec 2013 Preclinical trials in Glaucoma in Japan (unspecified route)
  • 31 Mar 2013 H 1129 licensed to Wakamoto Company in Japan
  • 31 Mar 2013 Early research in Glaucoma in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top